ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
20 announcements with these filters
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Sakar Healthcare's 22nd AGM was held on September 22, 2026, adopting audited financials and re-appointing a director. Routine resolutions were passed including secretarial auditor appointment.
Sakar Healthcare Limited received 14 oncology product approvals in the EU, UK, and Canada. These approvals for licensed-out products and site variations will drive top-line sales growth.
Sakar Healthcare Limited submitted its 22nd Annual General Meeting notice and the Annual Report for FY 2025-26. The meeting is scheduled for September 22, 2026.
Sakar Healthcare Q1 FY27 results show strong oncology pivot with 38% YoY revenue growth and 120% profit jump.
Sakar Healthcare reported strong Q1FY27 consolidated results with 38% Revenue growth and 120% PAT growth, driven by its vertically integrated oncology business and expansion into regulated markets.
Sakar Healthcare announced Q1FY27 results, reporting 38% YoY revenue growth. Strong operating performance was driven by oncology product contracts and global dossier approvals.
Sakar Healthcare Ltd reported revenue from operations of ₹73 Cr (+38.5% YoY) and net profit of ₹10.3 Cr (+119.1% YoY) for Q1 FY27.
Sakar Healthcare Limited has scheduled a board meeting for 24th July 2026 to consider and approve the unaudited financial results for the quarter ended 30th June 2026.
Cobra India (Mauritius) Limited, a non-promoter entity, sold 4,89,026 shares of Sakar Healthcare via the open market. Its stake decreased from 6.45% to 4.40%.
Sakar Healthcare clarified that its financial results filing had only heading and place-of-signing corrections. No financial figures or auditor opinion changed, reassuring investors.
Sakar Healthcare Q4 FY26 revenue grew 42% YoY to ₹71.1cr with 37% EBITDA margins. Strategy focuses on transforming into a pure-play oncology exporter via its EU GMP facility.
Sakar Healthcare signed an oncology supply agreement with Zydus Lifesciences for GCC markets. This strategic partnership expands its global footprint and strengthens its anti-cancer portfolio.
Sakar Healthcare Q4FY26 presentation highlights a strategic shift toward high-margin oncology, leveraging a new EU-GMP integrated API-FDF facility in Bavla to drive specialized global healthcare solutions.